Stock listing
Hamburg:3G0 Altimmune, Inc. Aktie
German listing (Hamburg) of Altimmune, Inc. · home listing NASDAQ:ALT
Follow Altimmune, Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:ALT
$1.33 USD -0.06 (-4.3%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:ALT
- Day range
- $1.32 – $1.46 USDNov 20, 2026
- Volume
- 4.02M sharesNov 20, 2026
- Market cap
- $258.8M USDAt the close on Nov 20, 2026 · price × 194.6M shares outstanding
- 52-week range
- $1.32 – $6.44 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $10.16M USDMedian day 3.51M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:ALT · Home | $1.33 USD | -0.06 (-4.3%) | 4,019,048 | $1.37 | $1.46 | $1.32 | $1.39 | Close on Nov 20, 2026 |
| Frankfurt:3G0 | €1.202 EUR | -0.072 (-5.7%) | 3,100 | €1.25 | €1.25 | €1.202 | €1.274 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ALT · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $1.33 | -0.06 | -4.3% | $1.37 | $1.46 | $1.32 | 4,019,048 | |
| $1.39 | -0.14 | -9.2% | $1.52 | $1.53 | $1.38 | 4,687,477 | |
| $1.53 | -0.03 | -1.9% | $1.55 | $1.56 | $1.495 | 4,245,713 | |
| $1.56 | -0.085 | -5.2% | $1.64 | $1.665 | $1.50 | 6,046,935 | |
| $1.645 | +0.035 | +2.2% | $1.64 | $1.67 | $1.58 | 3,501,696 | |
| $1.61 | -0.32 | -16.6% | $1.89 | $1.90 | $1.60 | 12,373,048 | |
| $1.93 | -0.01 | -0.5% | $1.95 | $1.985 | $1.90 | 2,921,884 | |
| $1.94 | -0.18 | -8.5% | $2.12 | $2.13 | $1.90 | 3,988,810 | |
| $2.12 | +0.04 | +1.9% | $2.097 | $2.21 | $2.05 | 4,360,690 | |
| $2.08 | +0.11 | +5.6% | $1.97 | $2.095 | $1.95 | 2,760,352 | |
| $1.97 | -0.15 | -7.1% | $2.12 | $2.127 | $1.91 | 4,191,051 | |
| $2.12 | +0.08 | +3.9% | $2.10 | $2.15 | $2.025 | 3,473,692 | |
| $2.04 | +0.02 | +1.0% | $2.03 | $2.08 | $2.03 | 2,385,659 | |
| $2.02 | -0.02 | -1.0% | $2.07 | $2.106 | $2.01 | 2,736,052 | |
| $2.04 | -0.10 | -4.7% | $2.10 | $2.13 | $1.99 | 3,514,346 | |
| $2.14 | +0.04 | +1.9% | $2.13 | $2.18 | $2.10 | 2,652,607 | |
| $2.10 | +0.06 | +2.9% | $2.02 | $2.10 | $1.995 | 4,313,240 | |
| $2.04 | -0.01 | -0.5% | $2.085 | $2.15 | $2.01 | 4,942,516 | |
| $2.05 | -0.07 | -3.3% | $2.14 | $2.14 | $2.02 | 3,485,419 | |
| $2.12 | -0.05 | -2.3% | $2.16 | $2.20 | $2.06 | 2,599,076 | |
| $2.17 | -0.06 | -2.7% | $2.20 | $2.24 | $2.15 | 3,089,620 | |
| $2.23 | -0.07 | -3.0% | $2.31 | $2.35 | $2.19 | 4,486,247 | |
| $2.30 | +0.07 | +3.1% | $2.22 | $2.32 | $2.20 | 2,229,237 | |
| $2.23 | +0.03 | +1.4% | $2.22 | $2.26 | $2.18 | 2,600,535 | |
| $2.20 | -0.16 | -6.8% | $2.365 | $2.369 | $2.17 | 4,240,400 | |
| $2.36 | +0.05 | +2.2% | $2.31 | $2.38 | $2.29 | 3,344,400 | |
| $2.31 | -0.12 | -4.9% | $2.40 | $2.41 | $2.29 | 5,623,700 | |
| $2.43 | -0.13 | -5.1% | $2.56 | $2.56 | $2.43 | 3,713,400 | |
| $2.56 | -0.05 | -1.9% | $2.59 | $2.625 | $2.56 | 2,158,700 | |
| $2.61 | +0.01 | +0.4% | $2.60 | $2.64 | $2.57 | 2,677,700 | |
| $2.60 | -0.06 | -2.3% | $2.66 | $2.66 | $2.55 | 4,929,500 | |
| $2.66 | -0.01 | -0.4% | $2.64 | $2.74 | $2.63 | 3,168,200 | |
| $2.67 | 0.00 | 0.0% | $2.70 | $2.70 | $2.64 | 7,623,300 | |
| $2.67 | -0.065 | -2.4% | $2.73 | $2.747 | $2.65 | 3,839,500 | |
| $2.735 | -0.025 | -0.9% | $2.80 | $2.81 | $2.71 | 4,243,900 | |
| $2.76 | -0.10 | -3.5% | $2.85 | $2.85 | $2.75 | 3,589,100 | |
| $2.86 | -0.11 | -3.7% | $2.99 | $2.99 | $2.86 | 4,922,500 | |
| $2.97 | +0.01 | +0.3% | $2.99 | $3.006 | $2.92 | 2,561,000 | |
| $2.96 | -0.10 | -3.3% | $3.04 | $3.07 | $2.95 | 3,357,500 | |
| $3.06 | +0.02 | +0.7% | $3.05 | $3.11 | $3.00 | 2,858,800 | |
| $3.04 | -0.15 | -4.7% | $3.18 | $3.20 | $2.98 | 3,685,800 | |
| $3.19 | -0.22 | -6.5% | $3.42 | $3.425 | $3.15 | 4,531,500 | |
| $3.41 | +0.14 | +4.3% | $3.33 | $3.41 | $3.25 | 4,003,300 | |
| $3.27 | +0.02 | +0.6% | $3.31 | $3.34 | $3.24 | 3,516,200 | |
| $3.25 | +0.01 | +0.3% | $3.23 | $3.26 | $3.18 | 12,175,800 | |
| $3.24 | 0.00 | 0.0% | $3.31 | $3.35 | $3.21 | 3,456,600 | |
| $3.24 | +0.01 | +0.3% | $3.27 | $3.29 | $3.195 | 3,328,800 | |
| $3.23 | -0.07 | -2.1% | $3.30 | $3.31 | $3.21 | 2,334,500 | |
| $3.30 | +0.03 | +0.9% | $3.27 | $3.36 | $3.27 | 2,460,900 | |
| $3.27 | -0.02 | -0.6% | $3.33 | $3.41 | $3.26 | 2,704,700 | |
| $3.29 | -0.06 | -1.8% | $3.32 | $3.345 | $3.25 | 2,563,000 | |
| $3.35 | -0.01 | -0.3% | $3.35 | $3.425 | $3.291 | 3,069,900 | |
| $3.36 | -0.06 | -1.8% | $3.46 | $3.55 | $3.34 | 3,588,400 | |
| $3.42 | +0.19 | +5.9% | $3.28 | $3.43 | $3.25 | 4,867,100 | |
| $3.23 | -0.05 | -1.5% | $3.30 | $3.32 | $3.19 | 2,550,400 | |
| $3.28 | +0.19 | +6.1% | $3.10 | $3.34 | $3.10 | 7,470,000 | |
| $3.09 | -0.02 | -0.6% | $3.07 | $3.095 | $3.02 | 2,355,200 | |
| $3.11 | 0.00 | 0.0% | $3.08 | $3.135 | $3.06 | 2,216,400 | |
| $3.11 | -0.13 | -4.0% | $3.21 | $3.23 | $3.06 | 3,188,500 | |
| $3.24 | +0.09 | +2.9% | $3.19 | $3.25 | $3.13 | 2,276,800 | |
| $3.15 | -0.05 | -1.6% | $3.20 | $3.20 | $3.09 | 4,046,200 | |
| $3.20 | +0.09 | +2.9% | $3.14 | $3.225 | $3.11 | 3,814,600 | |
| $3.11 | 0.00 | 0.0% | $3.13 | $3.13 | $3.025 | 2,715,900 | |
| $3.11 | +0.16 | +5.4% | $2.98 | $3.24 | $2.95 | 6,148,000 | |
| $2.95 | -0.17 | -5.4% | $3.07 | $3.08 | $2.92 | 4,681,400 |
Splits
1 split · NASDAQ:ALT · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-30 | Consolidation |
- Ticker
- Hamburg:3G0
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Hamburg
- Currency
- EUR
What changed lately
Latest news release · Nov 19, 2026
Altimmune to Participate in the 9th Annual Evercore Healthcare Conference
Latest earnings call · Nov 12, 2026
Altimmune (NASDAQ:ALT) Q3 2026 Earnings Call
Replay and transcript
Latest deck · Nov 9, 2026
Technical Presentation (November 2026)
Technical · 17 slides
Latest news
Altimmune to Participate in the 9th Annual Evercore Healthcare Conference
Nov 19, 2026
Closed $1.33 (-4.3%) on Nov 20, 2026
Altimmune Announces Third Quarter 2026 Financial Results and Business Update
Nov 12, 2026
Closed $1.61 (-16.6%) on Nov 12, 2026
Altimmune Announces Publication of IMPACT Phase 2b 48-Week Data in MASH in The Lancet Gastroenterology & Hepatology
Nov 12, 2026
Closed $1.61 (-16.6%) on Nov 12, 2026
Altimmune Presents Positive Late-Breaking Pemvidutide Data at AASLD The Liver Meeting® 2026 in Patients with Alcohol Use Disorder
Nov 9, 2026
Closed $2.12 (+1.9%) on Nov 9, 2026
Altimmune Announces Data from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder Selected as Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2026
Nov 5, 2026
Closed $1.97 (-7.1%) on Nov 5, 2026
Altimmune to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026
Nov 5, 2026
Closed $1.97 (-7.1%) on Nov 5, 2026
Altimmune Appoints Peter Greenleaf and Alex Howarth, Two Leading Biotech Executives, to Board of Directors to Support Its Strategic Evolution
Oct 27, 2026
Closed $2.04 (-0.5%) on Oct 27, 2026
Altimmune to Present New Data on Pemvidutide in Serious Liver Diseases at AASLD The Liver Meeting® 2026
Oct 19, 2026
Closed $2.23 (+1.4%) on Oct 19, 2026
Altimmune to Participate in Stifel Cardiometabolic Forum
Sep 23, 2026
Closed $3.19 (-6.5%) on Sep 23, 2026
Altimmune to Participate in the Wells Fargo 21st Annual Healthcare Conference
Sep 3, 2026
Closed $3.23 (-1.5%) on Sep 3, 2026
Altimmune, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 30 in the last 12 months · 179 in all · newest Nov 19, 2026 · oldest 2019
- Calls
- 27 calls with a replay · 27 with a transcript · latest Nov 12, 2026
- Decks
- 31 decks · latest Nov 9, 2026
Where Altimmune, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:ALT · Home listing | NASDAQ | United States | USD |
| gettex:3G0 | gettex | Germany | EUR |
| Lang & Schwarz:A2N5Z6 | Lang & Schwarz | Germany | EUR |
| LS Exchange:A2N5Z6 | LS Exchange | Germany | EUR |
| BMV:ALT1 | BMV | Mexico | MXN |
| BIVA:ALT1 | BIVA | Mexico | MXN |
| Tradegate:3G0 | Tradegate | Germany | EUR |
| BOATS:ALT | BOATS | United States | USD |
| LSE:0A4C | LSE | United Kingdom | USD |
| Dusseldorf:3G0 | Dusseldorf | Germany | EUR |
| Frankfurt:3G0 | Frankfurt | Germany | EUR |
| Hamburg:3G0 · This page | Hamburg | Germany | EUR |
| Munich:3G0 | Munich | Germany | EUR |
| Stuttgart:3G0 | Stuttgart | Germany | EUR |
Valuation
Price/book 0.6× against a median of 2.0×: the lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $28.73M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.6×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.1×
- Beta vs S&P 500
- 1.55
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Altimmune, Inc. · NASDAQ:ALT | US$258.8M | US$28.73M | n/a | n/a | n/a | 0.6× | n/a | 0.1× | 1.55 |
| Kyverna Therapeutics, Inc. · NASDAQ:KYTX | US$263.5M | US$117.8M | n/a | n/a | n/a | 2.0× | n/a | 0.2× | 2.02 |
| PepGen Inc. · NASDAQ:PEPG | US$261.8M | US$172.6M | n/a | n/a | n/a | 2.5× | n/a | 0.1× | 1.11 |
| Ocugen, Inc. · NASDAQ:OCGN | US$260.6M | US$178.1M | n/a | 37.3× | n/a | n/a | n/a | n/a | 1.47 |
| Prelude Therapeutics Incorporated · NASDAQ:PRLD | US$258.6M | US$136.2M | n/a | 6.3× | n/a | 2.1× | −247.1% | 0.1× | 1.48 |
| OBI Pharma, Inc. · TPEX:4174 | US$258.4M | US$243.3M | n/a | 154× | n/a | 5.7× | n/a | 0.0× | n/a |
| TransThera Sciences (Nanjing). Inc. · HKEX:2617 | US$257.1M | US$119.1M | n/a | n/a | n/a | 1.9× | n/a | 0.0× | n/a |
| Eikon Therapeutics, Inc. · NASDAQ:EIKN | US$256.8M | US$44.67M | n/a | n/a | n/a | 0.7× | n/a | 0.7× | 1.91 |
| SAB Biotherapeutics, Inc. · NASDAQ:SABS | US$255.7M | US$156.5M | n/a | n/a | n/a | 1.2× | n/a | 0.0× | 1.19 |
| Evommune, Inc. · NYSE:EVMN | US$255.5M | US$86.86M | n/a | n/a | n/a | 1.0× | n/a | 0.0× | 0.96 |
| Editas Medicine, Inc. · NASDAQ:EDIT | US$253.1M | US$119.7M | n/a | 2.4× | n/a | 3.0× | −144.9% | 0.7× | 2.22 |
| Median of the others | US$257.8M | US$128.0M | 21.8× | 2.0× | −196.0% | 0.1× | 1.48 |
Forecasts
7 strong buy · 2 buy · 1 hold · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 16.67 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.62 · 5 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Jerome Durso | President, Chief Executive Officer and Chairman Of The Board |
| Greg Weaver | Chief Financial Officer |
| Robin E. Abrams | Chief Legal Officer |
| Christophe Arbet-Engels | Chief Medical Officer |
| Linda M. Richardson | Chief Commercial Officer |
| Scot Roberts | Chief Scientific Officer |
Board
| Director | Role |
|---|---|
| Jerome Durso | President, Chief Executive Officer and Chairman Of The Board |
| Alex Howarth | Director |
| Catherine Angell Sohn | Director |
| Diane K. Jorkasky | Director |
| John M. Gill | Director |
| Mitchel Sayare | Director |
| Peter Greenleaf | Director |
| Philip Hodges | Director |
| Teri Lawver | Director |
| Wayne Pisano | Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| Altimmune (NASDAQ:ALT) Q3 2026 Earnings Call | Thu, Nov 12, 2026 · 8:30 AM ET | Replay |
| Altimmune (NASDAQ:ALT) Q2 2026 Earnings Call | Wed, Aug 12, 2026 · 8:30 AM ET | Replay |
| Altimmune (NASDAQ:ALT) Q1 2026 Earnings Call | Wed, May 13, 2026 · 8:30 AM ET | Replay |
| Altimmune (NASDAQ:ALT) Q4 2025 Earnings Call | Thu, Mar 05, 2026 · 8:30 AM ET | Replay |
| Altimmune (NASDAQ:ALT) Q3 2025 Earnings Call | Thu, Nov 06, 2025 · 8:30 AM ET | Replay |
| Altimmune (NASDAQ:ALT) Q2 2025 Earnings Call | Tue, Aug 12, 2025 · 8:30 AM ET | Replay |
| Altimmune (NASDAQ:ALT) Q1 2025 Earnings Call | Tue, May 13, 2025 · 8:30 AM ET | Replay |
| Altimmune (NASDAQ:ALT) Q4 2024 Earnings Call | Thu, Feb 27, 2025 · 8:30 AM ET | Replay |
| Altimmune (NASDAQ:ALT) Q3 2024 Earnings Call | Tue, Nov 12, 2024 · 8:30 AM ET | Replay |
| Altimmune (NASDAQ:ALT) Q2 2024 Earnings Call | Thu, Aug 08, 2024 · 8:30 AM ET | Replay |
All 27 calls
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 12, 2026 · Before open | −16.6% |
| Q2 2026 | Aug 12, 2026 · Before open | −2.3% |
| Q1 2026 | May 13, 2026 · Before open | −1.9% |
| Q4 2025 | Mar 26, 2026 | −8.8% |
| Q3 2025 | Nov 6, 2025 · Before open | +5.1% |
| Q2 2025 | Aug 12, 2025 · Before open | +7.1% |
| Q1 2025 | May 13, 2025 · Before open | −4.2% |
| Q4 2024 | Mar 25, 2025 · Before open | −2.6% |
| Q3 2024 | Nov 12, 2024 · Before open | +29.1% |
| Q2 2024 | Aug 8, 2024 · Before open | +15.1% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 9, 2024 · Before open | +7.8% |
| Q4 2023 | Mar 27, 2024 · Before open | +2.8% |
| Q3 2023 | Nov 7, 2023 · Before open | +1.1% |
| Q2 2023 | Aug 10, 2023 · Before open | +3.0% |
| Q1 2023 | May 11, 2023 · Before open | +7.0% |
| Q4 2022 | Feb 28, 2023 · Before open | +6.4% |
| Q3 2022 | Nov 10, 2022 · Before open | +9.2% |
| Q2 2022 | Aug 11, 2022 · After close | +26.1% |
| Q1 2022 | May 12, 2022 · Before open | +8.6% |
| Q4 2021 | Mar 15, 2022 · Before open | −8.2% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Technical Presentation (November 2026) | Technical | 17 slides | Nov 9, 2026 |
| AASLD The Liver Meeting 2026 | Conference | 19 slides | Nov 8, 2026 |
| Technical Presentation (November 2026) | Technical | 16 slides | Nov 7, 2026 |
| Q2 2026 Earnings Presentation | Earnings | 38 slides | Aug 12, 2026 |
| Technical Presentation (July 2026) | Technical | 19 slides | Jul 28, 2026 |
| Q4 2025 Earnings Presentation | Earnings | 32 slides | Mar 5, 2026 |
| Technical Presentation (December 2025) | Technical | 20 slides | December 2025 |
| Technical Presentation (June 2025) | Technical | 23 slides | Jun 26, 2025 |
| Investor Presentation (May 2025) | Investor deck | 39 slides | May 2025 |
| Technical Presentation (November 2023) | Technical | 19 slides | Nov 30, 2023 |
All 31 decks
Financings
| Raise | Date |
|---|---|
| Public offering of common stock and accompanying common stock warrants (or pre-funded warrants in lieu thereof) Closed: US$225M raised · US$3 a share · Warrants at US$3 · Leerink Partners +2 Dealers: Leerink Partners (co-lead), Barclays (co-lead), Titan Partners (co-lead) Buyers: Deep Track Capital (led the financing); TCGX; Viking Global Investors; RA Capital Management Use of proceeds: Fund the upcoming Phase 3 trial in MASH, plus working capital and general corporate purposes | Apr 27, 2026 |
| Registered direct offering of common stock (or pre-funded warrants in lieu thereof) Closed: US$75M raised · Titan Partners, a division of American Capital Partners Dealers: Titan Partners, a division of American Capital Partners (lead) Buyers: new fundamental institutional investor (17,045,454 shares of common stock (or pre-funded warrants in lieu thereof)) Use of proceeds: Upcoming Phase 3 trial in MASH, working capital and general corporate purposes | Jan 29, 2026 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 41.0K | 20.0K | 426.0K | -68.0K | 4.41M | 8.19M | 5.80M | 10.3M | 10.7M | 3.24M |
| Cost of revenue | 112.0K | 238.0K | 477.0K | 500.0K | 73.8M | 33.5M | 17.1M | 18.5M | 18.4M | 7.22M |
| Gross profit | 41.0K | 20.0K | 426.0K | -68.0K | 4.41M | -25.3M | 5.80M | -8.13M | -18.4M | -1.99M |
| Research and development | 66.4M | 82.2M | 65.8M | 70.5M | 74.5M | 49.8M | 17.8M | 18.5M | 18.4M | 7.22M |
| Selling, general and administrative | 28.1M | 21.0M | 18.1M | 17.1M | 15.4M | 13.2M | 8.50M | 9.77M | 8.46M | 11.5M |
| Operating income | -94.5M | -103.2M | -95.9M | -87.7M | -96.9M | -54.8M | -21.5M | -42.8M | -52.0M | -11.1M |
| Depreciation and amortization | 112.0K | 238.0K | 477.0K | -205.0K | 551.3K | 428.9K | 387.3K | 218.7K | 83.8K | 63.1K |
| EBITDA | -94.4M | -102.9M | -95.5M | -87.9M | -96.4M | -54.4M | -21.1M | -42.6M | -52.0M | -11.0M |
| Interest expense | 1.64M | 9.00K | 35.0K | 8.00K | 5.00K | 9.42K | 2.24K | 297.1K | 162.1K | 38.5K |
| Income before tax | -88.8M | -95.1M | -88.4M | -84.9M | -97.1M | -54.5M | -20.6M | -45.3M | -52.1M | -11.1M |
| Income tax | -681.0K | 309.1K | -197.0K | -919.5K | -5.42M | -58.5K | -6.15M | -5.64M | 0 | |
| Net income | -88.1M | -95.1M | -88.4M | -84.7M | -97.1M | -49.0M | -20.5M | -39.2M | -46.4M | -11.1M |
| Earnings per share, basic | -1.00 | -1.34 | -1.66 | -1.81 | -2.35 | -1.91 | -1.60 | -15.16 | -118.91 | 2.97 |
| Earnings per share, diluted | -1.00 | -1.34 | -1.66 | -1.81 | -2.35 | -1.91 | -1.60 | -15.16 | -118.91 | 2.95 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 43.8M | 36.9M | 135.1M | 111.1M | 190.3M | 115.9M | 8.96M | 33.7M | 8.77M | 2.88M |
| Short-term investments | 229.7M | 95.0M | 62.7M | 73.8M | 0 | 100.0M | 28.3M | 3.53M | 66.8M | |
| Receivables | 1.74M | 3.12M | 4.85M | 2.54M | 5.84M | 12.4M | 1.65M | 4.47M | 10.2M | 999.1K |
| Inventory | 34.0K | -13.4B | -1.96B | -503.9M | 3.53M | 0 | ||||
| Current assets | 278.2M | 137.3M | 209.6M | 192.8M | 204.1M | 230.3M | 39.4M | 39.4M | 23.5M | 4.49M |
| Property, plant and equipment | 312.0K | 413.0K | 651.0K | 1.08M | 1.45M | 1.06M | 1.10M | 1.34M | 603.1K | 177.9K |
| Goodwill | 0 | 0 | 0 | 18.8M | ||||||
| Total assets | 279.9M | 139.3M | 210.6M | 206.9M | 218.9M | 245.1M | 54.1M | 54.8M | 63.0M | 38.4M |
| Accounts payable | 2.72M | 211.0K | 2.07M | 4.80M | 2.03M | 612.3K | 18.2K | 372.9K | 129.1K | 2.01M |
| Current liabilities | 15.0M | 10.5M | 12.1M | 17.1M | 18.3M | 12.0M | 3.92M | 4.53M | 3.84M | 5.47M |
| Long-term debt | 34.3M | 4.58M | 1.45M | 1.83M | 1.86M | 1.85M | 4.57M | 526.0K | ||
| Total debt | 34.3M | 1.68M | 671.0K | 4.58M | 1.45M | 1.83M | 1.86M | 572.8K | 599.9K | 526.0K |
| Total liabilities | 55.0M | 15.8M | 16.5M | 21.6M | 19.7M | 19.2M | 8.54M | 6.44M | 14.4M | 6.19M |
| Shareholders' equity | 224.9M | 123.5M | 194.1M | 185.3M | 199.1M | 225.9M | 45.5M | 48.3M | 39.4M | 32.2M |
| Shares outstanding | 110.9M | 72.4M | 70.7M | 49.2M | 41.0M | 37.1M | 15.3M | 9.08M | 608.5K | 6.92M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -67.5M | -79.8M | -75.8M | -62.6M | -78.2M | -34.3M | -9.60M | -9.39M | -20.2M | -6.35M |
| Capital spending | -11.0K | 0 | -47.0K | -126.0K | -12.1M | -204.0K | -1.23K | -975.4K | -112.4K | -125.0K |
| Free cash flow | -67.5M | -79.8M | -75.9M | -62.7M | -90.4M | -34.5M | -9.60M | -10.4M | -20.3M | -6.48M |
| Cash from investing | -132.5M | -28.4M | 13.7M | -73.4M | 87.5M | -72.2M | -28.3M | -1.00M | 13.7M | -220.6K |
| Cash from financing | 206.8M | 10.0M | 86.1M | 56.8M | 65.1M | 213.5M | 12.5M | 32.5M | 15.8M | 4.98M |
| Dividends paid | -135.5M | -3.79B | -22.9K | 0 | 0 | |||||
| Share buybacks | 291.0K | 300.0K | 215.0K | -516.0K | 224.5M | 135.5M | 3.79B | -2.39M | 13.0M | 3.80M |
| Change in cash | 6.83M | -98.2M | 24.0M | -79.2M | 74.4M | 107.0M | -25.4M | 22.0M | 9.43M | 138.4M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 18, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 13, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 10, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 4, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 3 · Initial statement of ownership | Nov 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 4, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 4, 2026 | Insider trade | SEC |
| 8-K · Current report | Oct 29, 2026 | Financing | SEC |
| 8-K · Current report | Oct 27, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Oct 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 2, 2026 | Insider trade | SEC |
| 8-K · Current report | Sep 29, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Sep 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 13, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 12, 2026 | Results | SEC |
| 4 · Change in ownership | Aug 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 3, 2026 | Insider trade | SEC |
| 8-K · Current report | Jul 28, 2026 | Current report | SEC |
| 8-K · Current report | Jun 16, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | May 13, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | May 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 13, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | May 12, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 1, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 1, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | May 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 1, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | May 1, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | May 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 1, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 30, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Apr 24, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Apr 23, 2026 | Offer document | SEC |
| S-3MEF | Apr 22, 2026 | Other filings | SEC |
| 424B5 · Prospectus | Apr 22, 2026 | Offer document | SEC |
| 8-K · Current report | Apr 16, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | Apr 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 1, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 26, 2026 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Mar 17, 2026 | Annual report | SEC |
| DEF 14A · Proxy statement | Mar 17, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Mar 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 9, 2026 | Insider trade | SEC |
| PRE 14A · Preliminary proxy statement | Mar 6, 2026 | Meeting notice | SEC |
| 10-K · Annual report | Mar 6, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 5, 2026 | Results | SEC |
| 4 · Change in ownership | Feb 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 27, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Feb 6, 2026 | Offer document | SEC |
| 4 · Change in ownership | Feb 3, 2026 | Insider trade | SEC |
| 8-K · Current report | Feb 3, 2026 | Current report | SEC |
| 4 · Change in ownership | Feb 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 30, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 29, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 28, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Jan 28, 2026 | Offer document | SEC |
| 4 · Change in ownership | Jan 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Dec 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 22, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 19, 2025 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Dec 8, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Dec 3, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 1, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 1, 2025 | Management or board change | SEC |
| S-3/A · Registration statement, amended | Nov 13, 2025 | Offer document | SEC |
| 4 · Change in ownership | Nov 12, 2025 | Insider trade | SEC |
| S-3 · Registration statement | Nov 6, 2025 | Offer document | SEC |
| 8-K · Current report | Nov 6, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Nov 6, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2025 | Results | SEC |
| 4 · Change in ownership | Oct 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 3, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 3, 2025 | Insider trade | SEC |
| 8-K · Current report | Oct 3, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Sep 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 29, 2025 | Insider trade | SEC |
| 8-K · Current report | Sep 25, 2025 | Meeting outcome | SEC |
| 4 · Change in ownership | Sep 17, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 17, 2025 | Insider trade | SEC |
| UPLOAD · Letter from the SEC | Aug 19, 2025 | Other filings | SEC |
| ARS · Annual report to shareholders | Aug 15, 2025 | Annual report | SEC |
| DEF 14A · Proxy statement | Aug 15, 2025 | Meeting notice | SEC |
| CORRESP · Letter to the SEC | Aug 12, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 12, 2025 | Results | SEC |
| UPLOAD · Letter from the SEC | Aug 8, 2025 | Other filings | SEC |
| 4 · Change in ownership | Aug 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 4, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 16, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jun 26, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 13, 2025 | Results | SEC |
| 4 · Change in ownership | Mar 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 14, 2025 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Mar 14, 2025 | Other filings | SEC |
| 8-K · Current report | Mar 13, 2025 | Current report | SEC |
| 4 · Change in ownership | Mar 11, 2025 | Insider trade | SEC |
| CORRESP · Letter to the SEC | Mar 11, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Mar 5, 2025 | Other filings | SEC |
| S-3 · Registration statement | Feb 27, 2025 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Feb 27, 2025 | Offer document | SEC |
| 10-K · Annual report | Feb 27, 2025 | Annual report | SEC |
| 8-K · Current report | Feb 27, 2025 | Results | SEC |
| 4 · Change in ownership | Feb 26, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 25, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 25, 2025 | Insider trade | SEC |
| 8-K · Current report | Feb 25, 2025 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 7, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 5, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 11, 2024 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 12, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 12, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 12, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2024 | Results | SEC |
| 8-K · Current report | Nov 12, 2024 | Management or board change | SEC |
| SC 13G/A · Big-stake notice, amended | Oct 17, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Oct 16, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 30, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 30, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 30, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 30, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 30, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 30, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 30, 2024 | Insider trade | SEC |
| 8-K · Current report | Sep 26, 2024 | Meeting outcome | SEC |
| 4 · Change in ownership | Aug 20, 2024 | Insider trade | SEC |
| ARS · Annual report to shareholders | Aug 15, 2024 | Annual report | SEC |
| DEF 14A · Proxy statement | Aug 15, 2024 | Meeting notice | SEC |
| 8-K · Current report | Aug 15, 2024 | Management or board change | SEC |
| 10-Q · Quarterly report | Aug 8, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 8, 2024 | Results | SEC |
| 4 · Change in ownership | Aug 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 1, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Jul 10, 2024 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Jul 1, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 26, 2024 | Management or board change | SEC |
| 10-Q · Quarterly report | May 9, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 9, 2024 | Results | SEC |
| SC 13G/A · Big-stake notice, amended | Apr 10, 2024 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Mar 27, 2024 | Offer document | SEC |
| 10-K · Annual report | Mar 27, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 27, 2024 | Results | SEC |
| SC 13G · Big-stake notice | Mar 5, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 13, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 12, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 5, 2024 | Insider trade | SEC |
This page holds 200 of 1,001 filings. Open Filings
Cap table
Built by 6ix from Altimmune, Inc.’s releases · as of Nov 6, 2026
- Common shares
- 194,589,451
- Fully diluted
- 194,589,451
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 194,589,451 | Nov 6, 2026 |
Warrants and options
| Lot |
|---|
| Warrants · US$3.00 · expiry not stated |
Share count over time
| Count | Shares |
|---|---|
| Nov 6, 2026 | 194,589,451 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Catherine Angell Sohn Other companies: Maze Therapeutics, Inc. (Director · Since at least Jan 30, 2025); Axcella Health Inc (Director · Aug 21, 2019 – May 19, 2022 · Past); Rubius Therapeutics Inc (Director · Jul 17, 2018 – May 12, 2022 · Past); Palisade Bio, Inc. (Director · Jan 13, 2014 – Jul 1, 2015 · Past); Lifecore Biomedical, Inc. (Director · Nov 13, 2012 – Jun 4, 2022 · Past); Jazz Pharmaceuticals plc (Director · Jul 27, 2012 – Aug 11, 2023 · Past) | Director · Since at least Mar 23, 2023 |
| Brian A Markison Other companies: Organogenesis Holdings Inc. (Director · Oct 7, 2016 – Dec 10, 2018 · Past); Lantheus Holdings, Inc. (CEO, Director · Jun 24, 2015 – Mar 5, 2025 · Past); Alere Inc (Director · Aug 14, 2013 – Oct 3, 2017 · Past); Immunomedics Inc (Director · Aug 24, 2006 – Nov 20, 2017 · Past); King Pharmaceuticals Inc (President and CEO, Director · Mar 20, 2006 – Feb 28, 2011 · Past) | Director · Sep 22, 2011 – Dec 31, 2014 · Past |
| James H Cavanaugh Other companies: Cypherpunk Technologies Inc. (Director · Since at least Jan 20, 2017); Verenium Corp (Director · Jul 20, 2006 – Oct 31, 2013 · Past); Medimmune Inc (Director · Jun 30, 2006 – Jun 18, 2007 · Past); MiddleBrook Pharmaceuticals Inc (Director · May 24, 2006 – Jun 23, 2009 · Past) | Director · Aug 3, 2007 – Nov 3, 2010 · Past |
| Derace L Schaffer Other companies: Lantheus Holdings, Inc. (Director · Mar 4, 2016 – Mar 3, 2020 · Past); American Caresource Holdings Inc (Director · Jul 20, 2010 – Jun 14, 2012 · Past); King Pharmaceuticals Inc (Director · May 14, 2010 – Jan 31, 2011 · Past) | Director · May 17, 2010 – Dec 28, 2017 · Past |
| Steven St Peter Other companies: Aratana Therapeutics Inc (PRESIDENT AND CEO, Director · Jun 26, 2013 – Dec 17, 2018 · Past); Radius Health, Inc. (President, Director · Jun 15, 2008 – Jun 15, 2008 · Past); Omrix Biopharmaceuticals Inc (Director · Apr 11, 2006 – Sep 4, 2008 · Past) | Director · Aug 6, 2007 – Jan 4, 2017 · Past |
| Christophe Arbet-Engels Other companies: X4 Pharmaceuticals, Inc. (Chief Medical Officer · Aug 16, 2023 – Nov 4, 2026 · Past); Tempest Therapeutics, Inc. (Chief Medical Officer · Feb 10, 2020 – May 25, 2020 · Past) | Chief Medical Officer · Since at least Oct 1, 2025 |
| Edward B Berger Other companies: Conmed Healthcare Management Inc (Director · Feb 21, 2012 – Aug 28, 2012 · Past); American Caresource Holdings Inc (Director · Jun 28, 2007 – Aug 28, 2015 · Past) | Director · Dec 31, 2006 – Dec 31, 2006 · Past |
| Jeffrey W Runge Other companies: Aditxt, Inc. (Director · Jul 10, 2020 – Nov 8, 2023 · Past); Conmed Healthcare Management Inc (Director · Jan 14, 2011 – Aug 28, 2012 · Past) | Director · Dec 17, 2009 – Jan 20, 2017 · Past |
| Linda M. Richardson Other companies: Intercept Pharmaceuticals Inc (EVP & Chief Commercial Officer · Feb 15, 2021 – Nov 8, 2023 · Past); Chimerix Inc (Chief Commercial Officer · Jan 8, 2014 – May 14, 2018 · Past) | Chief Commercial Officer · Since at least Sep 16, 2025 |
| Richard I Eisenstadt Other companies: Aytu BioPharma, Inc. (Chief Financial Officer · Mar 31, 2021 – Mar 31, 2021 · Past); Neos Therapeutics Inc (Chief Financial Officer · Mar 2, 2020 – Mar 19, 2021 · Past) | Chief Financial Officer · Dec 31, 2021 – Jan 30, 2024 · Past |
All 41 people
| Person | Seat |
|---|---|
| Teri Lawver Other companies: Celldex Therapeutics, Inc. (Senior Vice President, Chief Commercial Officer · Since at least Nov 10, 2025); DexCom, Inc. (EVP Chief Commercial Officer · Jan 9, 2023 – Mar 12, 2024 · Past) | Director · Since at least Feb 24, 2025 |
| Vipin K Garg Other companies: Neos Therapeutics Inc (Chief Executive Officer · Jul 22, 2015 – Mar 1, 2018 · Past); Ocera Therapeutics Inc (President & CEO, Director · Apr 1, 2011 – Aug 7, 2012 · Past) | Director · Since at least Nov 30, 2018 |
| Wayne Pisano Other companies: Oncolytics Biotech Inc. (Director · Since at least Jun 26, 2025); Provention Bio Inc (Director · Jul 3, 2018 – Apr 27, 2023 · Past) | Director · Since at least Aug 30, 2018 |
| William Enright Other companies: BullFrog AI Holdings, Inc. (Director · Since at least Feb 13, 2023); Vaccitech plc (Chief Executive Officer, Director · Apr 29, 2021 – Mar 27, 2023 · Past) | President and CEO, Director · May 4, 2017 – May 25, 2018 · Past |
| David P Wright Other companies: Achillion Pharmaceuticals Inc (Director · Aug 20, 2007 – Dec 18, 2012 · Past) | President and CEO, Director · Aug 3, 2007 – Dec 11, 2009 · Past |
| Diane K. Jorkasky Other companies: Tengion Inc (Director · Aug 10, 2011 – May 21, 2012 · Past) | Director · Since at least May 11, 2020 |
| Gregory L Weaver Other companies: Atossa Therapeutics, Inc. (Former EVP, CFO, & Director, Director · May 17, 2019 – Nov 15, 2023 · Past) | Chief Financial Officer · Since at least Nov 11, 2024 |
| Jerome Durso Other companies: Intercept Pharmaceuticals Inc (CEO, Director · Feb 23, 2017 – Nov 8, 2023 · Past) | President, Chief Executive Officer and Chairman Of The Board · Since at least Feb 24, 2025 |
| John M. Gill Other companies: Tetralogic Pharmaceuticals Corp (Director · Dec 11, 2013 – Dec 31, 2013 · Past) | Director · Since at least Jun 11, 2013 |
| Mitchel Sayare Other companies: ImmunoGen Inc (Director · Jan 31, 2006 – Jul 29, 2011 · Past) | Director · Since at least Apr 27, 2010 |
| Alex Howarth | Director · Since at least Oct 27, 2026 |
| Andrew Shutterly | Acting Chief Financial Officer · Jun 26, 2024 – Jul 31, 2024 · Past |
| David Drutz | Director · May 4, 2017 – Aug 19, 2024 · Past |
| Francesca M Cook | SVP, Policy & Gov't Affairs · Dec 1, 2011 – Dec 8, 2014 · Past |
| Greg Weaver | Chief Financial Officer · Since at least Sep 15, 2025 |
| Jeffrey Michael Jones | COO · Mar 11, 2015 – Mar 11, 2015 · Past |
| Joan Fusco | SVP, Operations · Feb 4, 2008 – May 6, 2010 · Past |
| Joel McCleary | Director · Jun 23, 2010 – Dec 31, 2014 · Past |
| Jordan P Karp | SVP, General Counsel · Jun 30, 2008 – Dec 3, 2012 · Past |
| Klaus Schafer | Director · Since at least May 4, 2017 |
| Matthew Scott Harris | Chief Medical Officer · Since at least Sep 9, 2019 |
| Peter Greenleaf | Director · Since at least Oct 27, 2026 |
| Philip Hodges | Director · Since at least Nov 4, 2026 |
| Philip Hodges | Director · Since at least May 4, 2017 |
| Philip Macneill | VP, CFO, Treasurer, Secretary · Sep 8, 2011 – Dec 21, 2016 · Past |
| Raymond M Jordt | Chief Business Officer · Since at least Jan 3, 2023 |
| Richard Thomas Menziuso | Principal Accounting Officer · Since at least Nov 18, 2026 |
| Robin E. Abrams | Chief Legal Officer · Since at least Nov 6, 2025 |
| Scot Roberts | Chief Scientific Officer · Since at least May 4, 2017 |
| Sybil Tasker | Chief Medical Officer · May 4, 2017 – Jun 17, 2019 · Past |
| Thomas Richard Fuerst | EVP, Chief Scientific Officer · Apr 5, 2010 – Dec 1, 2011 · Past |
Log in to ask 6ix AI your own questions about Altimmune, Inc.